Telomere Therapeutics is a gene therapy company developing disease modifying treatments for unmet medical needs, pioneering the repair of telomeres to treat organ fibrosis and other telomere-dysfunction syndromes for which there are no curative treatments.
Our lead program is an AAV-based therapy primarily focused on idiopathic pulmonary fibrosis (iPF), a disease with very poor prognosis and a high mortality rate, estimated at <5 years after diagnosis.
Thus far our results demonstrate, for the first time ever, the capacity to revert disease in animal model*. Our goal is to make this drug a reality for iPF patients.
*Ref: Povedano JM, Martinez P, Serrano R, Tejera Á, Gómez-López G, Bobadilla M, Flores JM, Bosch F, Blasco MA. Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres. Elife. 2018 Jan 30;7:e31299. doi: 10.7554/eLife.31299.